Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.…
Profusa Announces Progress Towards Satisfying the Conditions to Close of the Option Agreement with G3
Profusa (NASDAQ: PFSA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector.
The shares were at 0.3234 USD on 20 November 2026, down 99.9% over 52 weeks. Its 52-week range is 0.3100 USD to 378.75 USD: the price is 99.9% below the high and 4.3% above the low.
Its market capitalisation is 1.84M USD.
Profusa reports return on equity of 134.4% and an operating margin of 0.0%.
Its debt exceeds its cash by 13.38M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.
No upcoming events tracked.